Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07499713

Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata

The goal of this observational study is to learn about microvascular changes and hair follicle activity in patients with alopecia areata. The main questions it aims to answer are:

Do blood levels of markers related to blood vessel formation (VEGF-A) and inflammation (VCAM-1) differ between patients with alopecia areata and healthy individuals?

Is there a link between these blood markers and structural changes in the nailfold capillaries?

How do these markers relate to specific trichoscopic signs of disease activity (such as black dots or exclamation mark hairs) and the overall severity of hair loss (SALT score)?

Researchers will compare patients with alopecia areata (grouped by disease duration: acute <6 months vs. chronic >6 months) to healthy volunteers to see if there is a significant difference in systemic and local vascular indicators.

Participants will:

Undergo a trichoscopic scalp examination to identify markers of disease activity (black dots, yellow dots, exclamation mark hairs) and calculate the SALT score.

Have their nailfolds examined with a digital capillaroscope (50x) to detect microvascular alterations.

Provide a blood sample to measure the levels of VEGF-A and VCAM-1.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul Education and Research Hospital

Istanbul, Turkey (Türkiye)

About this study

Alopecia areata (AA) is a common autoimmune form of non-scarring hair loss. Although the exact cause is unknown, it is thought that inflammation and changes in the microvasculature (small blood vessels) play a significant role. This study aims to investigate the systemic and local vascular components of the disease.

The study includes 60 patients diagnosed with alopecia areata and 30 age- and sex-matched healthy volunteers. Patients are categorized into two groups based on disease duration:

Acute Group: Patients with a disease duration of less than 6 months.

Chronic Group: Patients with a disease duration of 6 months or longer.

Methodology and Procedures:

Dermatological and Trichoscopic Examination: All patients undergo a clinical examination using a Dermlite 5 dermatoscope. The severity of hair loss is calculated using the SALT (Severity of Alopecia Tool) score. Trichoscopic markers of disease activity, including black dots, yellow dots, exclamation mark hairs, broken hairs, vellus hairs, and pigtail hairs, are recorded according to Rudnicka's criteria.

Nailfold Capillaroscopy: To evaluate local microvascular alterations, nailfold capillaroscopy is performed using a Dino-Lite digital microscope (50x magnification). Examinations are conducted on the 2nd to 5th fingers of both hands after a 15-minute acclimatization period in a temperature-controlled room (20-23 °C). Morphological changes such as capillary dilatation, tortuosity, hemorrhages, and avascular areas are documented. An "abnormal pattern" is defined as the presence of two or more abnormalities in at least two fingers.

Biochemical Analysis: Venous blood samples are collected from all participants. After centrifugation, serum is separated and stored at -80 °C. Serum levels of Vascular Endothelial Growth Factor A (VEGF-A) and Vascular Cell Adhesion Molecule 1 (VCAM-1) are measured using the ELISA method.

The study will analyze the correlation between these biochemical markers, trichoscopic activity signs, and capillaroscopic findings to better understand the vascular pathogenesis of alopecia areata across different disease stages.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: Participants aged between 18 and 60 years.
  • Diagnosis: Clinical and trichoscopic diagnosis of Alopecia Areata (AA) by a dermatologist.
  • Categorization: "Acute" (<6 months duration) or "Chronic" (≥6 months duration) groups.
  • Consent: Ability to provide written informed consent for participation in the study.

Exclusion criteria

  • Medical History: Patients with a history of diabetes mellitus, autoimmune diseases, connective tissue diseases, chronic inflammatory or vascular diseases.
  • Pregnancy & Lactation: Pregnancy or breastfeeding.
  • Lifestyle Factors: Active smoking or chronic alcohol use.
  • Hair & Nail Conditions: Causes of hair loss other than alopecia areata, the presence of any nail disease, or having had a manicure within the last 3 weeks.

Treatment and study plan

Microvascular Imaging

Diagnostic Test

his intervention focuses on the integration of microvascular and biochemical markers to phenotype Alopecia Areata subgroups.

Other names: Nailfold Capillaroscopy, NVC

Biochemical Biomarker Analysis

Diagnostic Test

Collection of 5-10 mL venous blood samples. Serum is separated by centrifugation (3000 RPM, 10 min) and analyzed via Enzyme-Linked Immunosorbent Assay (ELISA) to determine the levels of Vascular Endothelial Growth Factor A and Vascular Cell Adhesion Molecule 1.

Other names: Serum VEGF-A, Serum VCAM-1

Trichoscopic Imaging

Diagnostic Test

his non-invasive procedure focuses on identifying specific trichoscopic patterns associated with Alopecia Areata activity, including yellow dots, black dots, exclamation mark hairs, and broken hairs.

Other names: Trichoscopy, Dermoscopy

Primary outcomes

  1. Serum Levels of VEGF-A and VCAM-1

    Time frame: At enrollment (Baseline - Single time point)

    Serum concentrations of Vascular Endothelial Growth Factor A and Vascular Cell Adhesion Molecule 1 will be measured to evaluate systemic vascular involvement and endothelial activation in patients with Alopecia Areata.

Secondary outcomes

  1. Nailfold Capillaroscopic Patterns

    Time frame: At enrollment

    Assessment of microvascular morphology (dilatation, tortuosity, hemorrhages) using a 50x digital microscope.

  2. Correlation with SALT Score and Trichoscopic Signs

    Time frame: At enrollment

    Evaluation of the relationship between serum biomarkers (VEGF-A, VCAM-1) and clinical severity (SALT score) or activity signs (exclamation mark hairs, black dots).

Sponsors and collaborators

Lead sponsor

Istanbul Training and Research Hospital

Other Gov

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 30, 2026
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.